T1	Participants 428 540	218 patients with previously untreated HD entered this study: 106 patients in arm A (ABVD/MOPP) and 112 in arm B
T2	Participants 553 561	Patients
T3	Participants 657 665	Patients
T4	Participants 906 948	two arms in terms of CR rate and toxicity.
T5	Participants 999 1007	patients
T6	Participants 1105 1113	patients
